Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Neuro Endocrinology Letters
|
November 20, 2012
Hypnic headache - a rare primary headache disorder with very good response to indomethacin
David Dolezil, Charis Mavrokordatos
Journal of Pain Research
|
November 19, 2020
An Investigation into the Prevalence of Migraine and Its Prophylactic Treatment Patterns in the Czech Republic: An Observational Study
David Dolezil, Jolana Markova, Jiri Klimes, et al.
Cephalalgia : an International Journal of Headache
|
July 10, 2018
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
Messoud Ashina, Stewart Tepper, Jan Lewis Brandes, et al.
Advances in Therapy
|
September 20, 2021
Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
Uwe Reuter, Christian Lucas, David Dolezil, et al.
Neuro Endocrinology Letters
|
April 3, 2012
Physiotherapy as an immunoactive therapy? A pilot study
Kamila Rasova, David Dolezil, Hana Kalistova, et al.
Cephalalgia : an International Journal of Headache
|
December 10, 2019
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response
Jan Lewis Brandes, Hans-Christoph Diener, David Dolezil, et al.
Cephalalgia : an International Journal of Headache
|
November 12, 2019
Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions
Messoud Ashina, David Kudrow, Uwe Reuter, et al.
JAMA Neurology
|
March 25, 2024
Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial
Patricia Pozo-Rosich, David Dolezil, Koen Paemeleire, et al.
European Journal of Neurology
|
August 21, 2025
Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo-Controlled Study
Stewart J Tepper, David W Dodick, Michel Lanteri-Minet, et al.
JAMA Neurology
|
September 16, 2024
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial
Stewart J Tepper, David W Dodick, Michel Lanteri-Minet, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Neuro Endocrinology Letters
|
November 20, 2012
Hypnic headache - a rare primary headache disorder with very good response to indomethacin
David Dolezil, Charis Mavrokordatos
Journal of Pain Research
|
November 19, 2020
An Investigation into the Prevalence of Migraine and Its Prophylactic Treatment Patterns in the Czech Republic: An Observational Study
David Dolezil, Jolana Markova, Jiri Klimes, et al.
Cephalalgia : an International Journal of Headache
|
July 10, 2018
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
Messoud Ashina, Stewart Tepper, Jan Lewis Brandes, et al.
Advances in Therapy
|
September 20, 2021
Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
Uwe Reuter, Christian Lucas, David Dolezil, et al.
Neuro Endocrinology Letters
|
April 3, 2012
Physiotherapy as an immunoactive therapy? A pilot study
Kamila Rasova, David Dolezil, Hana Kalistova, et al.
Cephalalgia : an International Journal of Headache
|
December 10, 2019
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response
Jan Lewis Brandes, Hans-Christoph Diener, David Dolezil, et al.
Cephalalgia : an International Journal of Headache
|
November 12, 2019
Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions
Messoud Ashina, David Kudrow, Uwe Reuter, et al.
JAMA Neurology
|
March 25, 2024
Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial
Patricia Pozo-Rosich, David Dolezil, Koen Paemeleire, et al.
European Journal of Neurology
|
August 21, 2025
Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo-Controlled Study
Stewart J Tepper, David W Dodick, Michel Lanteri-Minet, et al.
JAMA Neurology
|
September 16, 2024
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial
Stewart J Tepper, David W Dodick, Michel Lanteri-Minet, et al.
Page
of 1